Several drugs against Covid-19 already in clinical trials


Nurses wearing protective face masks checking into duty and entering a community hospital in Shanghai. Several antiviral drugs have been applied in clinical trials against the Covid-19 disease (coronavirus), and some have shown fairly good clinical efficacy, according to an official on Saturday (Feb 15). - AFP

BEIJING: Several antiviral drugs have been applied in clinical trials against the Covid-19 disease (coronavirus), and some have shown fairly good clinical efficacy, according to an official on Saturday (Feb 15).

Chinese researchers have narrowed down their focus to a few existing drugs, including Chloroquine Phosphate, Favipiravir and Remdesivir, after multiple rounds of screening, said Zhang Xinmin, director of the China National Centre for Biotechnology Development under the Ministry of Science and Technology, at a press conference on the new virus.

In vitro experiments have shown that Chloroquine Phosphate, an antimalarial drug which has been widely used for many years, can effectively inhibit the novel coronavirus infection.

It is now under clinical trials in more than 10 hospitals in Beijing and Guangdong, which enrolled a total of over 100 patients. Clinical trials on the drug will also be launched in central China's Hunan Province soon, Zhang said.

The preliminary clinical results show that Chloroquine Phosphate is quite effective in treating novel coronavirus pneumonia, he said.

Favipiravir, an influenza drug available on overseas markets, has been put in a clinical trial in Shenzhen, south China's Guangdong Province, with 70 patients enlisted, he said.

The initial outcome of the trial shows the drug has relatively obvious efficacy and low adverse reactions.

"Three to four days after treatment, the group that takes the drug has a significantly higher turning-negative rate in the viral nucleic acid than the parallel group," he said.

Remdesivir is developed against Ebola infections by Gilead Sciences, an American pharmaceutical company. It has shown fairly good antiviral activity against the novel coronavirus at the cellular level.

The China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences have been authorized to conduct a clinical trial on the drug in over 10 hospitals in Wuhan, the center of the epidemic in central China's Hubei Province.

"Next, we will make timely recommendations on the COVID-19 treatment according to the results of these clinical trials," Zhang said.

According to him, the researchers scanned more than 70,000 drugs or compounds through computer simulations and in vitro enzyme activity tests, and selected 5,000 potentially effective drug candidates.

Then they were tested at the cellular level against the common coronavirus infection, and about 100 drugs were chosen for further experiments, which helped to select the final drugs for clinical trials, Zhang said.

The most urgent scientific research task is to improve the cure rate and reduce the mortality, which rely on effective clinical treatments, he noted.

New products and technologies have been adopted to treat severe and critically ill patients, a key approach to reduce mortality, and some have achieved good clinical effects, he said.

One of the recent progresses is the development of convalescent plasma. It is processed from the plasma collected from recovered patients, which contains a large amount of protective antibodies.

So far, a total of 11 severe patients from several hospitals in Wuhan have received the convalescent plasma therapy, with all their clinical indicators getting better and no obvious adverse reactions.

Clinical studies on the stem cell therapy, which can inhibit the overreaction of the body's immune system, have also been carried out to treat severe patients, he added.

A cause of death for severe and critically ill patients infected with the COVID-19 is "cytokine storm", which is an overreaction of the immune system, according to Zhou Qi, an academician with the Chinese Academy of Sciences (CAS).

"We are also searching for existing drugs that can curb the appearance of cytokine storm, including drugs against rheumatism. Some of the drugs that are proven effective at the cellular level have been applied in clinical trials," Zhou said at the press conference.

A trial has been conducted on 14 severe or critically ill patients aged up to 82 in an affiliated hospital of the University of the CAS, and the results appeared encouraging, Zhou said.

"Now, a multicenter, randomised, parallel-group clinical trial is underway. If the initial results show a drug is effective, we may speed up the process and provide severe patients with effective treatments as soon as possible," he added. - Xinhua/Asian News Network
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3

Covid-19. Treatment , Drugs

   

Did you find this article insightful?

Yes
No

Next In Regional

Twin sisters score Japan’s hottest IPO by making games for women
Covid-19: Cases up by 2,063, bringing total to 307,943 (updated daily)
Thailand probes Facebook’s removal of army-linked accounts
ByteDance developing Clubhouse-like app for China amid copycat rush, sources say
Recycling old smartphones is not only good for the environment – it is a potentially lucrative business for e-waste companies in China
Khairy: MySejahtera users only need to apply once for vaccination
Two more M'sian university programmes make it into top 100 of QS World ranking
Hoteliers laud move to relax international borders
Community group buying: Chinese regulators fine businesses tied to Big Tech for price dumping
Asean economic ministers propose common digital vaccine certificate, says Azmin Ali

Stories You'll Enjoy


Vouchers